Taltz ® (ixekizumab)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).

Taltz® (ixekizumab): Dosage Regimen for Plaque Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis

Information on the dosing schedule of Ixekizumab depending on the indication is provided below.


Ixekizumab Dosage Regimen

Please note that this statement solely focuses on the posology of Ixekizumab. Please find further information, e.g. on indications, method of administration, concomitant medication etc. in the Taltz label information.1

Plaque Psoriasis

Plaque Psoriasis in adults

The recommended dose is

  • 160 mg by subcutaneous injection (two 80 mg injections) at week 0,
  • followed by 80 mg (one injection) at weeks 2, 4, 6, 8, 10, and 12,
  • then maintenance dosing of 80 mg (one injection) every 4 weeks.1

Paediatric plaque psoriasis (age 6 years and above)

Efficacy and safety data is not available in children below the age of 6 years.1

Available data do not support a posology below a body weight of 25 kg.1

The recommended dose given by subcutaneous injection in children is based on the following weight categories1

Children’s body weight

Recommended starting dose (week 0)

Recommended dose every 4 weeks (Q4W) thereafter

Greater than 50 kg

160 mg (two 80 mg injections)

80 mg

25 to 50 kg

80 mg

40 mg

Pre-filled syringe

For children prescribed 80 mg, ixekizumab can be used directly from the prefilled syringe.1

For instructions on preparation of ixekizumab 40 mg, see section 6.6 of the Taltz Summary of Product Characteristics.1

  • Doses less than 80 mg must be prepared by a healthcare professional.1

Ixekizumab is not recommended for use in children with a body weight below 25 kg.1

Paediatric body weights must be recorded and regularly re-checked prior to dosing.1

Pre-filled pen

Ixekizumab doses of 40 mg must be prepared and administered by a qualified healthcare professional using the commercial Taltz 80 mg/1 ml prefilled syringe.1

Use the Taltz 80 mg pre-filled pen only in those children that require a dose of 80 mg and do not require dose preparation.1

Ixekizumab is not recommended for use in children with a body weight below 25 kg. Paediatric body weights must be recorded and regularly re-checked prior to dosing.1

Psoriatic Arthritis

The recommended dose is

  • 160 mg by subcutaneous injection (two 80 mg injections) at Week 0,
  • followed by 80 mg (one injection) every 4 weeks thereafter.1

For psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis, the recommended dosing regimen is the same as for plaque psoriasis.1

Axial Spondyloarthritis (Radiographic and Non-radiographic)

The recommended dose is

  • 160 mg (two 80 mg injections) by subcutaneous injection at Week 0,
  • followed by 80 mg every 4 weeks.1

Special Populations

Elderly (≥ 65 years)

No dose adjustment is required in elderly patients (≥65 years).1

There is limited information in subjects aged ≥75 years.1

Renal or hepatic impairment

Ixekizumab has not been studied in patients with renal or hepatic impairment. No dose recommendations can be made.1

All indications - Response

For all indications (plaque psoriasis in adults and children, psoriatic arthritis, axial spondyloarthritis) consideration should be given to discontinuing treatment in patients who have shown no response after 16 to 20 weeks of treatment.1

  • Some patients with initially partial response may subsequently improve with continued treatment beyond 20 weeks.1


1Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland

Date of Last Review: 17 June 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request